Wang Lai 4

What Happened

• Wang Lai, President and Global Head of R&D at BeOne Medicines (ONC), disposed of 1,068 ADS on 2026-06-23 at $276.74 each, totaling $295,553. The transaction is reported as a sale (S) but was effected to satisfy mandatory tax withholding tied to the vesting of restricted stock units (RSUs).

Key Details

• Transaction date and price: 2026-06-23 — 1,068 shares @ $276.74; proceeds $295,553.
• Filing date / timeliness: Report filed 2026-06-25 (within the normal two-business-day Form 4 reporting window).
• Reason for sale: Mandatory tax withholding on vested RSUs (footnote F6). The RSU award vests in quarterly/anniversary increments (1/4 vests each year since June 22, 2022), subject to continued service and certain acceleration events.
• Ownership reporting notes: The filing discloses holdings through Wang Holdings LLC and participation in an RMB-shares employee plan; the reporting person disclaims beneficial ownership of certain plan-held shares (see footnotes F1–F4). Each American Depositary Share (ADS) represents 13 ordinary shares (F5).
• Shares owned after the reported transaction: Not specified in the provided excerpt of the filing.

Context

• This sale was a tax-withholding disposition tied to RSU vesting (routine for executives) rather than an open-market decision to reduce exposure. Such withholding sales are common and do not necessarily indicate a view on company prospects.
• Transaction code: S = Sale; the sale was effected pursuant to a tax-withholding provision (per footnote F6).